Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

Yasuhiro Oki, Hagop M. Kantarjian, Vazganush Gharibyan, Dan Jones, Susan O'Brien, Srdan Verstovsek, Jorge Cortes, Gail M. Morris, Guillerrno Garcia-Manero, Jean Pierre J. Issa

Research output: Contribution to journalArticlepeer-review

122 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences